Sonelokimab is a novel humanized nanobody that selectively binds to interleukin (IL)-17A and IL-17F.
SAN DIEGO — After 24 weeks of treatment with subcutaneously administered sonelokimab 120 mg, about 43% of patients with moderate to severe achieved a Hidradenitis Suppurativa Clinical Response , defined as at least a 75% reduction in total abscess and inflammatory nodule count with no increase in abscess or draining tunnel count relative to baseline, results from a randomized clinical trial showed., a dermatologist at St.
At 24 weeks, 43.3% of patients in the sonelokimab 120 mg arm achieved a HiSCR 75, compared with 34.8% of those in the sonelokimab 240 mg arm and 14.7% of those in the placebo arm, he reported. Meanwhile, 65.7% of patients in the sonelokimab 120 mg arm achieved an HiSCR 75, compared with 53% of those in the sonelokimab 240 mg arm and 27.9% of those in the placebo arm.
In addition, complete inflammatory remission as defined by the International HS Severity Score System continued to increase to week 24, with 24.1% of patients in the 120 mg arm achieving complete remission, compared with 15.5% of those in the 240 mg arm. Meaningful improvements in quality of life, skin pain, and HS symptoms reported by patients treated with sonelokimab were maintained or increased to week 24.
Biologics Skin And Soft Tissue Infection Hidradenitis Suppurativa Abscess Interleukins Nodule Remission Suicide Depression Antigens Board Certification Boards Board Recertification Clinical Research Clinical Trials Clinical Studies Pre-Clinical Trial Double-Blind Study Double-Blind Studies Single-Blind Study Single-Blind Studies Epidemiology Hospitals Liver
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Subcutaneously Administered Sonelokimab Shows Promising Results in Treating Hidradenitis SuppurativaResults from a randomized clinical trial showed that about 43% of patients with moderate to severe Hidradenitis Suppurativa achieved a significant reduction in abscess and inflammatory nodule count after 24 weeks of treatment with subcutaneously administered sonelokimab 120 mg. Sonelokimab, a smaller monoclonal antibody, has the potential to penetrate tissues better and provide longer-lasting effects. The therapy is being developed by MoonLake Immunotherapeutics.
Read more »
Ruxolitinib Cream Shows Promise in Reducing Abscess and Inflammatory Nodule Count in Hidradenitis SuppurativaPatients with hidradenitis suppurativa (HS) who applied ruxolitinib cream experienced a greater reduction in the abscess and inflammatory nodule count compared to those who used a vehicle cream, according to a phase 2 trial.
Read more »
Ruxolitinib Cream Shows Promise for Hidradenitis SuppurativaTreatment with the topical JAK inhibitor reduced abscess and inflammatory nodules in a phase 2 randomized, controlled trial in patients with mild hidradenitis suppurativa.
Read more »
Maternal Hidradenitis Suppurativa Linked to Risk for Childhood Morbidity: StudyThe study population included nearly 1.3 million children born in Quebec, Canada, over a 16-year period.
Read more »
TV Shows That Desrved A Season 2 Vs. Shows That Didn'tA League of Their Own deserved at least one more season, but if I'm being honest I could've done with only one season of Big Little Lies.
Read more »
I’m a Woman Living With HS. Here’s How I Navigate Dating and RelationshipsHidradenitis suppurativa adds a layer of complexity to finding a relationship in a looks-driven world. Here's how Imani Futrell handles her dating life.
Read more »